Key Considerations When Developing a DOAC – Part 1

NOAC
Share this:
Print Friendly, PDF & Email

 

Atrial fibrillation (AF) and Venous Thromboembolism (VTE) are long term conditions affecting millions of people globally. AF is one of the major risk factors for stroke. While Vitamin K antagonists (VKAs) such as warfarin has been the traditional standard of care for over sixty years, the introduction of Direct Oral Anticoagulants (DOACs) have given physicians and patients an additional treatment options for stroke prevention in AF and for the treatment of VTE. In this part one of the four-part whitepaper, we start with the introduction to AF and VTE and the current standard of care.


Click here to download

Related Post

Preeti Parikh
Preeti Parikh
Preeti has been with RAS since its inception in 2014. She has worked on several projects involving strategy development, competitive intelligence and market analysis. She is passionate about data which she combines with her natural knack for visualisation and creating engaging content. Preeti began her career with a Masters Degree in Biotechnology from University of Abertay

Leave a Reply

Your email address will not be published. Required fields are marked *

*